DLCL
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
Rights
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Dr Lalchandani Labs do?
Dr Lalchandani Labs Limited is a leading provider of diagnostic and healthcare tests in Delhi/NCR, offering a wide range of services for patient care and disease prevention.
Who are the competitors of Dr Lalchandani Labs?
Dr Lalchandani Labs major competitors are Global Longlife Hosp, Transgene Biotek, Gian Life Care, DhanvantriJeevan Rek, Family Care Hospital, Broach Lifecare Hosp, Clinitech Laboratory. Market Cap of Dr Lalchandani Labs is ₹14 Crs. While the median market cap of its peers are ₹11 Crs.
Is Dr Lalchandani Labs financially stable compared to its competitors?
Dr Lalchandani Labs seems to be less financially stable compared to its competitors. Altman Z score of Dr Lalchandani Labs is 2.75 and is ranked 4 out of its 8 competitors.
Does Dr Lalchandani Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Dr Lalchandani Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Dr Lalchandani Labs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable
How strong is Dr Lalchandani Labs balance sheet?
Balance sheet of Dr Lalchandani Labs is moderately strong.
Is the profitablity of Dr Lalchandani Labs improving?
The profit is oscillating. The profit of Dr Lalchandani Labs is ₹0.42 Crs for Mar 2025, ₹0.62 Crs for Mar 2024 and -₹1.56 Crs for Mar 2023
Is the debt of Dr Lalchandani Labs increasing or decreasing?
Yes, The net debt of Dr Lalchandani Labs is increasing. Latest net debt of Dr Lalchandani Labs is ₹1.07 Crs as of Sep-25. This is greater than Mar-25 when it was ₹0.56 Crs.
Is Dr Lalchandani Labs stock expensive?
Dr Lalchandani Labs is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Dr Lalchandani Labs is 34.71, while 3 year average PE is 12.33. Also latest EV/EBITDA of Dr Lalchandani Labs is 12.52 while 3yr average is 13.49.
Has the share price of Dr Lalchandani Labs grown faster than its competition?
Dr Lalchandani Labs has given better returns compared to its competitors. Dr Lalchandani Labs has grown at ~32.97% over the last 1yrs while peers have grown at a median rate of -43.36%
Is the promoter bullish about Dr Lalchandani Labs?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Dr Lalchandani Labs is 31.15% and last quarter promoter holding is 48.32%
Are mutual funds buying/selling Dr Lalchandani Labs?
There is Insufficient data to gauge this.
